New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT06421935
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers will also look for any signs that the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
M9466 (PARP1 inhibitor), tuvusertib, abiraterone acetate, prednisone/prednisolone
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 60 participants, so it is too soon to know if the drug works. The main goal is safety, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea
-
Cancer Institute Hospital of JFCR
Kōtoku, Japan
-
Cancer Research SA
Adelaide, Australia
-
Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica
Madrid, Spain
-
GenesisCare North Shore (Oncology)
St Leonards, Australia
-
Harasanshin Hospital
Fukuoka, Japan
-
Hospital HM Nou Delfos - START Barcelona
Barcelona, Spain
-
Hospital Universitari Vall d'Hebron - Oncology Dept.
Barcelona, Spain
-
Hospital Universitario 12 de Octubre - Servicio de Oncologia
Madrid, Spain
-
Hospital Universitario Fundacion Jimenez Diaz - START Madrid FJD - Oncology Phase I
Madrid, Spain
-
ICO l'Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia
Barcelona, Spain
-
NEXT Madrid - Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Spain
-
NEXT Oncology - PARENT
New York, New York, 10065, United States
-
NHO Kumamoto Medical Center - Dept of Urology
Kumamoto, Japan
-
National Cancer Center Hospital East - Dept of Experimental Therapeutics
Kashiwa-shi, Japan
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital, Yonsei University Health System - Division of Infectious Diseases
Seoul, South Korea
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States